Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects

被引：0
|
作者：
Navin Goyal
Pete Skrdla
Rosemary Schroyer
Subramanya Kumar
Disala Fernando
Anna Oughton
Nicola Norton
Dennis L. Sprecher
Joseph Cheriyan
机构：
[1] GlaxoSmithKline,GlaxoSmithKline Clinical Unit Cambridge
[2] Addenbrooke’s Hospital,undefined
[3] Cambridge University Hospitals NHS Foundation Trust,undefined
来源：
American Journal of Cardiovascular Drugs | 2019年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：335 / 342
页数：7
相关论文
共 24 条
  • [1] Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects
    Goyal, Navin
    Skrdla, Pete
    Schroyer, Rosemary
    Kumar, Subramanya
    Fernando, Disala
    Oughton, Anna
    Norton, Nicola
    Sprecher, Dennis L.
    Cheriyan, Joseph
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2019, 19 (03) : 335 - 342
  • [2] A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMISED, CROSSOVER STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF TRPV4 INHIBITOR GSK2798745 IN PARTICIPANTS WITH CHRONIC COUGH
    Ludbrook, V. J.
    Hanrott, K. E.
    Marks-Konczalik, J.
    Kreindler, J. L.
    Bird, N. P.
    Hewens, D.
    Beerahee, M.
    Behm, D. J.
    Morice, A.
    McGarvey, L.
    Parker, S. M.
    Birring, S. S.
    Smith, J.
    THORAX, 2019, 74 : A18 - A18
  • [3] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06650833, a Novel, Potentially First-in-Class Inhibitor of Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) in Healthy Subjects
    Danto, Spencer
    Shojaee, Negin
    Li, Cheryl
    Gilbert, Steven A.
    Singh, Ravi Shankar
    Manukyan, Zorayr
    Kilty, Iain
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [4] Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects
    Scherrer, Didier
    Rouzier, Regine
    Barrett, P. Noel
    Steens, Jean-Marc
    Gineste, Paul
    Murphy, Robert L.
    Tazi, Jamal
    Ehrlich, Hartmut J.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (03) : 820 - 828
  • [5] Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes
    Allas, S.
    Delale, T.
    Ngo, N.
    Julien, M.
    Sahakian, P.
    Ritter, J.
    Abribat, T.
    van der Lely, A. J.
    DIABETES OBESITY & METABOLISM, 2016, 18 (09): : 868 - 874
  • [6] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of Amg 986, a Novel Small Molecule Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients
    Hellawell, Jennifer
    Abbasi, Siddique
    Trivedi, Ashit
    Tsirtsonis, Kate
    Kaufman, Allegra
    JOURNAL OF CARDIAC FAILURE, 2020, 26 (10) : S68 - S68
  • [7] The novel elastase inhibitor BAY 85-8501: First-in-man study to evaluate safety, tolerability and pharmacokinetics in healthy male subjects
    Nagelschmitz, Johannes
    Becka, Michael
    Kaufel, Dorina
    Schwers, Stephan
    von Nussbaum, Franz
    Li, Volkhart
    Wensing, Georg
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [8] Non clinical pharmacology, pharmacokinetics and safety profiling of CB-103: A novel first-in-class small molecule inhibitor of the NOTCH pathway
    Lehal, Rajwinder
    Frismantas, Viktoras
    Urech, Charlotte
    Murone, Maximilien
    Weber, Dirk
    Bauer, Michael
    Bourquin, Jean-Pierre
    Radtke, Freddy
    CANCER RESEARCH, 2017, 77
  • [9] Multiple-dose clinical pharmacology of the first-in-class CXCR7 antagonist ACT-1004-1239: safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship in healthy subjects
    Huynh, Christine
    Brussee, Janneke M.
    Fonseca, Marlene
    zu Schwabedissen, Henriette E. Meyer
    Dingemanse, Jasper
    Sidharta, Patricia N.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (SUPPL 1) : 35 - 36
  • [10] PHASE 1 MULTIPLE ASCENDING DOSE STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS/PHARMACODYNAMICS OF AG-348, A FIRST-IN-CLASS ALLOSTERIC ACTIVATOR OF PYRUVATE KINASE-R, IN HEALTHY SUBJECTS
    Yang, H.
    Merica, E.
    Chen, Y.
    Cohen, M.
    Goldwater, R.
    Kim, H.
    Kosinski, P.
    Kung, C.
    Goldwasser, M.
    Silver, B.
    Utley, L.
    Agresta, S.
    HAEMATOLOGICA, 2015, 100 : 18 - 18
123